Charles River Laboratories International (NYSE:CRL) EVP Shannon Parisotto Sells 2,039 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 2,039 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $294.12, for a total value of $599,710.68. Following the completion of the sale, the executive vice president owned 4,807 shares of the company’s stock, valued at $1,413,834.84. This represents a 29.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Trading Up 1.0%

Shares of Charles River Laboratories International stock opened at $292.97 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $13.99 billion, a P/E ratio of -60.41, a price-to-earnings-growth ratio of 3.00 and a beta of 1.38. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $299.32. The company has a 50-day simple moving average of $232.83 and a 200 day simple moving average of $193.15.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. During the same quarter last year, the business earned $3.12 earnings per share. The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Research analysts expect that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current fiscal year.

Institutional Trading of Charles River Laboratories International

Institutional investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC bought a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $42,000. Sfam LLC bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at $43,000. Activest Wealth Management grew its stake in shares of Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after acquiring an additional 218 shares during the period. Elyxium Wealth LLC bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at $46,000. Finally, Geneos Wealth Management Inc. increased its position in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on CRL. Citigroup reaffirmed a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. Mizuho set a $264.00 price target on Charles River Laboratories International in a report on Monday, August 10th. Barclays restated an “overweight” rating and set a $300.00 price target on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Morgan Stanley raised their price target on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a report on Wednesday, July 1st. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $255.65.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.